R. Somers

发表

Cellular transformation of NIH3T3 fibroblasts by CIZ/NMP4 fusions

P. Marynen, A. Corveleyn, J. Cools, 2005, Journal of cellular biochemistry.

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view.

M. van Glabbeke, J. Verweij, M. Glabbeke, 1995, Critical reviews in oncology/hematology.

Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective.

J. Verweij, A. Santoro, A. V. van Oosterom, 1992, Annals of Oncology.

European Experience of Adjuvant Chemotherapy for Soft Tissue Sarcoma: Interim Report of a Randomized Trial of Cyvadic Versus Control

R. Sylvester, A. Santoro, V. Bramwell, 1988 .

Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas

R. Sylvester, A. Santoro, H. Mouridsen, 2004, Cancer Chemotherapy and Pharmacology.

Chemotherapy in Advanced Soft Tissue Sarcoma — The EORTC Experience

J. Mulder, R. Sylvester, A. Santoro, 1988 .

Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group

R. Sylvester, A. Santoro, H. Mouridsen, 1984, Cancer.

Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study.

J. Mulder, R. Sylvester, A. Santoro, 1983, European journal of cancer & clinical oncology.

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.

A. Hagenbeek, M. Henry-Amar, B. D. de Pauw, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.

A. Hagenbeek, E. Noordijk, L. Bijnens, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.

J. Blay, A. Hagenbeek, P. Biron, 1998, Blood.

A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma. An EORTC Soft Tissue and Bone Sarcoma Group Study.

H. Keizer, J. Verweij, R. Sylvester, 1989, European journal of cancer & clinical oncology.

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.

R. Sylvester, A. Santoro, H. Mouridsen, 1987, European journal of cancer & clinical oncology.

MALT1 Auto-Proteolysis Is Essential for NF-κB-Dependent Gene Transcription in Activated Lymphocytes

P. Marynen, M. Thome, M. Baens, 2014, PloS one.

Auto-Ubiquitination-Induced Degradation of MALT1-API2 Prevents BCL10 Destabilization in t(11;18)(q21;q21)-Positive MALT Lymphoma

P. Marynen, H. Noels, C. de Wolf‐Peeters, 2009, PloS one.

Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.

C. Seynaeve, J. Verweij, A. Santoro, 1992, European Journal of Cancer.

Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease.

M. Henry-Amar, R. Somers, 1990, Seminars in oncology.

Effective systemic therapy for spinal epidural metastases from breast carcinoma.

W. Boogerd, J. Van Der Sande, R. Somers, 1989, European journal of cancer & clinical oncology.

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.

J. Verweij, A. Santoro, H. Mouridsen, 1993, Cancer chemotherapy and pharmacology.

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D. Crowther, J. Verweij, T. Tursz, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy.

M. Tubiana, E. Van Der Schueren, M. Henry-Amar, 1984, International journal of radiation oncology, biology, physics.

Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group

J. Verweij, M. Glabbeke, W. Steward, 2005, Journal of Cancer Research and Clinical Oncology.

Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation

M. van Glabbeke, M. Glabbeke, P. Voûte, 1988, Cancer.

EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.

C. de Wolf‐Peeters, U. Tirelli, A. Delmer, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).

A. Hagenbeek, B. Coiffier, C. Gisselbrecht, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, A. Santoro, 1993, Cancer chemotherapy and pharmacology.

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype

G. Thomas, P. Marynen, A. Yoshimura, 2007, Nature Genetics.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

A. Hagenbeek, B. Coiffier, P. Sonneveld, 1995, The New England journal of medicine.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.

H. Mouridsen, A. V. van Oosterom, V. Bramwell, 1982, European journal of cancer & clinical oncology.

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.

A. Hagenbeek, P. Sonneveld, C. Gisselbrecht, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

M. van Glabbeke, D. Crowther, J. Verweij, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.

A. Hagenbeek, M. van Glabbeke, S. Pittaluga, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

Peter Marynen, Jan Cools, Carlos Graux, 2005, Blood.

Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia.

P. Marynen, A. Hagemeijer, R. Foà, 2002, Cancer research.

The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group.

M Tubiana, E. Noordijk, M. Tubiana, 1992, European journal of cancer.

Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group.

E. Noordijk, J. Cosset, M. Henry-Amar, 1990, International journal of radiation oncology, biology, physics.

A multivariate analysis of prognostic factors in early stage Hodgkin's disease.

M. Tubiana, M. Henry-Amar, P. Carde, 1985, International journal of radiation oncology, biology, physics.

Fusion of EML 1 to ABL 1 in T-cell acute lymphoblastic leukemia with cryptic t ( 9 ; 14 ) ( q 34 ; q 32 )

Peter Marynen, Jan Cools, Carlos Graux, 2005 .

Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation.

A. Hagenbeek, S. Pittaluga, C. de Wolf‐Peeters, 1996, Blood.

Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, H. Mouridsen, 1989, European journal of cancer & clinical oncology.

A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma

R. Souhami, M. Nooij, M. Glabbeke, 1999 .

A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).

M. van Glabbeke, R. Souhami, D. Machin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor

P. Marynen, A. Hagemeijer, P. Pauwels, 2002, Genes, chromosomes & cancer.

Reproducibility and prognostic value of different non-Hodgkin's lymphoma classifications: study based on the clinicopathologic relations found in the EORTC trial (20751).

J. Diebold, P. Heerde, M. van Glabbeke, 1985, European journal of cancer & clinical oncology.

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.

A. Craft, P. Voûte, A. V. van Oosterom, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

M Van Glabbeke, M. van Glabbeke, E. Noordijk, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Mulder, L. Bastholt, A. Santoro, 1987, European journal of cancer & clinical oncology.

Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer.

J. Mulder, A. Santoro, H. Mouridsen, 1988, Seminars in surgical oncology.

Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Bramwell, R. Sylvester, P. Voûte, 1985, Cancer treatment reports.

VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group.

A. Santoro, H. Mouridsen, V. Bramwell, 1987, European journal of cancer & clinical oncology.

Phase II study of elliptinium in metastatic soft tissue sarcoma.

A. V. van Oosterom, J. Rouëssé, D. Thomas, 1985, European journal of cancer & clinical oncology.

The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).

A. Hagenbeek, B. Coiffier, C. Gisselbrecht, 1991, Bone Marrow Transplantation.

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

A. Hagenbeek, M. van Glabbeke, M. Glabbeke, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide plus Adriamycin in Advanced Soft Tissue Sarcomas

R. Sylvester, A. Santoro, H. Mouridsen, 1987 .

The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1990, European journal of cancer.

The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma.

M. van Glabbeke, H. Keizer, D. Crowther, 1999, European Journal of Cancer.

Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

A. Ferrando, D. Gilliland, A. Look, 2004, Nature Genetics.

The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.

D. Crowther, J. Verweij, T. Tursz, 1993, Cancer chemotherapy and pharmacology.

Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, P. Woll, 1991, European journal of cancer.

The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach.

A. Hart, P. Heerde, B. Taal, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer.

J. Mulder, R. Sylvester, H. Mouridsen, 1986, Cancer treatment reports.

Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group.

A. Santoro, H. Mouridsen, A. V. van Oosterom, 1984, Cancer treatment reports.